^
Association details:
| Biomarker: | DDR + PD-L1 expression |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Comprehensive biomarker analyses and updated results of PURE-01 study: Neoadjuvant pembrolizumab (pembro) in muscle-invasive urothelial bladder carcinoma (MIBC)
Published date:
10/01/2018
Excerpt:
Pembro is given 200mg q3w x3 cycles. Pathologic complete response (pT0) in ITT population is the primary endpoint (EP)….8/8 pts (100%) with DDR/RB1 GA and CPS≥21% achieved pT0.
DOI:
https://doi.org/10.1093/annonc/mdy283.075
Trial ID:
